申请人:Pharmacia & Upjohn S.p.A.
公开号:US06060483A1
公开(公告)日:2000-05-09
The present invention provides the new use in the treatment of neurodegenerative diseases with ergoline derivatives of formula (I) ##STR1## wherein R.sub.1 represents a hydrogen atom or a linear or branched C.sub.1 -C.sub.5 alkyl or C.sub.2 -C.sub.5 alkenyl group optionally substituted with a C.sub.3 -C.sub.7 cycloalkyl, a hydroxy group or a R.sub.3 -substituted phenyl group wherein R.sub.3 is a hydroxy or a hydroxymethyl group; R.sub.2 represents a hydrogen atom or a linear or branched C.sub.1 -C.sub.5 alkyl or a C.sub.2 -C.sub.5 alkenyl group optionally substituted with a hydroxy group, or a R.sub.3 -substituted phenyl group wherein R.sub.3 is as above defined, or with a C.sub.1 -C.sub.5 alkoxy group; the symbols--at positions 2,3 and 8, 9 independently denote a single or double chemical bond and Z represents a group (CH.sub.2).sub.n OH, wherein n is 0 or an integer from 1 to 3, or a group C(R.sub.4).sub.2 OH wherein R.sub.4 is a C.sub.1 -C.sub.5 alkyl or a phenyl group, or a pharmaceutically acceptable salt thereof. Some compounds of formula (I) are novel. Processes for their preparation and pharmaceutical compositions containing them are also described.
本发明提供了使用式(I)的埃哥林衍生物治疗神经退行性疾病的新用途:其中R.sub.1代表氢原子或线性或支链C.sub.1-C.sub.5烷基或C.sub.2-C.sub.5烯基基团,可选地被C.sub.3-C.sub.7环烷基、羟基或R.sub.3-取代的苯基团所取代,其中R.sub.3是羟基或羟甲基基团;R.sub.2代表氢原子或线性或支链C.sub.1-C.sub.5烷基或C.sub.2-C.sub.5烯基基团,可选地被羟基或R.sub.3-取代的苯基团所取代,其中R.sub.3如上所定义,或被C.sub.1-C.sub.5烷氧基所取代;位置2、3和8、9上的符号独立地表示单个或双重化学键,Z表示(CH.sub.2).sub.n OH基团,其中n为0或1到3的整数,或C(R.sub.4).sub.2 OH基团,其中R.sub.4是C.sub.1-C.sub.5烷基或苯基团,或其药学上可接受的盐。式(I)的一些化合物是新的。还描述了它们的制备过程和含有它们的制药组合物。